Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

O'Neill: UK 'Lost Focus' On Antibiotic Crisis And Pharma Must Do More

Executive Summary

The time for talking is over when it comes to antimicrobial resistance, says Jim O'Neill, urging the government to 'rediscover the passion for championing' initiatives in the UK, notably the new AMR Centre in Alderley Park near Manchester.

You may also be interested in...



New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.

O'Neill Warns Pharma Risks Backlash If Doesn't Engage In World AMR Pact

The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.

Zymeworks Cuts C-Suite In Half At Crunch Time For Pipeline

New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel